valproic acid has been researched along with Insulin Resistance in 31 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the last years, a growing body of literature indicates an association between valproic acid therapy and weight gain." | 8.87 | Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. ( Chiarelli, F; Coppola, G; D'Egidio, C; Mohn, A; Verrotti, A, 2011) |
| "To investigate the presence of insulin resistance in obese children with idiopathic epilepsy on valproic acid (VPA) monotherapy in comparison to obese otherwise healthy subjects." | 7.81 | Insulin resistance in patients on valproic acid: relation to adiponectin. ( Aly, RH; Amr, NH; Megahed, AA; Saad, WE, 2015) |
| "Valproic acid (VPA), as one of the most widely prescribed antiepileptic drugs (AED) for many types of epilepsy in adults and children, is associated with weight gain, alteration of adipocytokine homeostasis, insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD)." | 7.79 | The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? ( Ebenbichler, CF; Laimer, M; Luef, G; Rauchenzauner, M; Salzmann, K; Sandhofer, A; Sturm, W; Tschoner, A; Walser, G; Wiedmann, M, 2013) |
| "To investigate the possible role of valproic acid therapy in the development of the weight gain and hyperinsulinemia of epileptic patients." | 7.72 | [Insulin resistance in epileptic patients during treatment of valproic acid]. ( Bao, YY; Chen, Z; Ding, MP; Liu, ZR; Xu, LL, 2004) |
| "In order to investigate the possible role of valproic acid therapy in the development of obesity, hyperinsulinism and polycystic ovaries (PCOs), we have studied metabolic parameters and ovarian morphology in epileptic women." | 7.71 | Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. ( Abraham, I; Alge, A; Bauer, G; Haslinger, M; Lechleitner, M; Luef, G; Seppi, K; Trinka, E; Unterberger, I; Windisch, J, 2002) |
| " Leptin is considered a signaling factor regulating body weight and energy metabolism." | 7.71 | Serum insulin and leptin levels in valproate-associated obesity. ( Isojärvi, JI; Knip, M; Kotila, M; Pakarinen, A; Pylvänen, V; Turkka, J, 2002) |
| "Valproic acid is effective for treatment of many types of epilepsy, but its use in epileptic patients can be associated with an increase in body weight that could interfere with treatment compliance." | 7.71 | Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. ( Basciani, F; Chiarelli, F; De Simone, M; Morgese, G; Trotta, D; Verrotti, A, 2002) |
| "Treatment with metformin or rosiglitazone prevents excess adrenal androgen synthesis." | 5.34 | Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. ( Bahtiyar, G; Sacerdote, AS; Weiss, K, 2007) |
| " Valproic acid appears to be use cautionally in obese females with epilepsy." | 5.24 | Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study. ( Sadhotra, A; Sidhu, HS; Srinivas, R, 2017) |
| " Weight gain is a significant side effect of valproic acid, which has not been clearly identified pathogenetically." | 5.12 | The role of ghrelin in weight gain and growth in epileptic children using valproate. ( Akinci, A; Gungor, S; Ozerol, IH; Tabel, Y; Yologlu, S; Yücel, G, 2007) |
| "A significant weight gain and increase in serum leptin levels in the course of antiepileptic treatment with valproic acid (VPA) has been described in several clinical studies." | 5.10 | Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. ( Abraham, I; Bauer, G; Hoppichler, F; Lechleitner, M; Luef, G; Trinka, E; Unterberger, I, 2002) |
| "Body mass index (BMI) and fasting serum concentrations of insulin and lipids were measured in 102 men with epilepsy who were treated with VPA, carbamazepine (CBZ), or oxcarbazepine (OXC) monotherapy." | 5.10 | Fasting serum insulin and lipid levels in men with epilepsy. ( Isojärvi, JI; Knip, M; Kotila, M; Myllylä, VV; Pakarinen, AJ; Pylvänen, V; Rättyä, J; Turkka, J, 2003) |
| " VPA-induced weight gain seems to be associated with many metabolic disturbances; the most frequent are hyperinsulinemia and insulin resistance, hyperleptinemia and leptin resistance." | 4.89 | Metabolic and endocrine effects of valproic acid chronic treatment. ( Belcastro, V; D'Egidio, C; Striano, P; Verrotti, A, 2013) |
| "In the last years, a growing body of literature indicates an association between valproic acid therapy and weight gain." | 4.87 | Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. ( Chiarelli, F; Coppola, G; D'Egidio, C; Mohn, A; Verrotti, A, 2011) |
| "Valproic acid (VPA), a widely used antiepileptic drug, has broad-spectrum activity against both generalized and partial epilepsy." | 4.85 | Valproate-induced insulin resistance and obesity in children. ( Chiarelli, F; la Torre, R; Mohn, A; Trotta, D; Verrotti, A, 2009) |
| "Valproic acid (2-n-propylpentanoic acid, VPA) is well-established as a mood-stabilizer for bipolar disorder, in addition to its application as a treatment in neurological disorders such as epilepsy, migraine headaches, and chronic neuropathic pain." | 4.84 | Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. ( Rasgon, NL; Reynolds, MF; Sisk, EC, 2007) |
| "To investigate the presence of insulin resistance in obese children with idiopathic epilepsy on valproic acid (VPA) monotherapy in comparison to obese otherwise healthy subjects." | 3.81 | Insulin resistance in patients on valproic acid: relation to adiponectin. ( Aly, RH; Amr, NH; Megahed, AA; Saad, WE, 2015) |
| "Valproic acid (VPA), as one of the most widely prescribed antiepileptic drugs (AED) for many types of epilepsy in adults and children, is associated with weight gain, alteration of adipocytokine homeostasis, insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD)." | 3.79 | The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? ( Ebenbichler, CF; Laimer, M; Luef, G; Rauchenzauner, M; Salzmann, K; Sandhofer, A; Sturm, W; Tschoner, A; Walser, G; Wiedmann, M, 2013) |
| "We recruited 98 patients with epilepsy (45 taking phenytoin, 27 taking valproate, and 26 not taking any AED)." | 3.78 | Characterization of glucose homeostasis and lipid profile in adult, seizure-free, epileptic patients in Asian population. ( Geater, A; Limapichat, K; Phabphal, K; Sathirapanya, P; Setthawatcharawanich, S, 2012) |
| "Our study was carried out to ascertain the role of valproic acid for inducing metabolic disorders like hyperinsulinemia, insulin resistance and metabolic syndrome." | 3.77 | Fasting insulin and HOMA-index changes in patients treated with valproic acid. ( Javashvili, L; Kasradze, S; Mania, M; Okujava, N, 2011) |
| "This study was undertaken in 2 parts to investigate the relationship between body size and insulin resistance during treatment with valproic acid in children." | 3.76 | Weight gain and insulin resistance in children treated with valproate: the influence of time. ( Chiarelli, F; Chiavaroli, V; de Giorgis, T; Giannini, C; Masuccio, F; Mohn, A; Verrotti, A, 2010) |
| "Chronic antiepileptic therapy with valproic acid (VPA) is associated with increased body weight and insulin resistance in adults and children." | 3.74 | Adiponectin and visfatin concentrations in children treated with valproic acid. ( Ebenbichler, CF; Ernst, B; Haberlandt, E; Hoppichler, F; Karall, D; Luef, G; Rauchenzauner, M; Rostasy, K; Scholl-Bürgi, S, 2008) |
| "To investigate the possible role of valproic acid therapy in the development of the weight gain and hyperinsulinemia of epileptic patients." | 3.72 | [Insulin resistance in epileptic patients during treatment of valproic acid]. ( Bao, YY; Chen, Z; Ding, MP; Liu, ZR; Xu, LL, 2004) |
| "In order to investigate the possible role of valproic acid therapy in the development of obesity, hyperinsulinism and polycystic ovaries (PCOs), we have studied metabolic parameters and ovarian morphology in epileptic women." | 3.71 | Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. ( Abraham, I; Alge, A; Bauer, G; Haslinger, M; Lechleitner, M; Luef, G; Seppi, K; Trinka, E; Unterberger, I; Windisch, J, 2002) |
| " Leptin is considered a signaling factor regulating body weight and energy metabolism." | 3.71 | Serum insulin and leptin levels in valproate-associated obesity. ( Isojärvi, JI; Knip, M; Kotila, M; Pakarinen, A; Pylvänen, V; Turkka, J, 2002) |
| "Valproic acid is effective for treatment of many types of epilepsy, but its use in epileptic patients can be associated with an increase in body weight that could interfere with treatment compliance." | 3.71 | Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. ( Basciani, F; Chiarelli, F; De Simone, M; Morgese, G; Trotta, D; Verrotti, A, 2002) |
| "Valproic acid (VPA) is an anti-epileptic drug used in patients with convulsive seizures and psychic disorders." | 1.43 | High-calorie diet inflates steatogenic effects of valproic acid in mice. ( Anuradha, CV; Bhavani, K; Sathiya Priya, C, 2016) |
| "Metabolic syndrome was more frequently associated with VPA-treated patients (41." | 1.34 | Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. ( Kim, JY; Lee, HW, 2007) |
| "Treatment with metformin or rosiglitazone prevents excess adrenal androgen synthesis." | 1.34 | Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. ( Bahtiyar, G; Sacerdote, AS; Weiss, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (54.84) | 29.6817 |
| 2010's | 11 (35.48) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| George, LJ | 1 |
| Singh, P | 1 |
| Aneja, S | 1 |
| Singh, R | 1 |
| Solanki, RS | 1 |
| Seth, A | 1 |
| Liu, J | 1 |
| Teng, Z | 1 |
| Xie, H | 1 |
| Yuan, H | 1 |
| Liu, M | 1 |
| Chen, J | 1 |
| Tang, H | 1 |
| Xiang, H | 1 |
| Wu, H | 1 |
| Huang, J | 1 |
| Adegoke, TE | 1 |
| Sabinari, IW | 1 |
| Usman, TO | 1 |
| Abdulkareem, TO | 1 |
| Michael, OS | 1 |
| Adeyanju, OA | 1 |
| Dibia, C | 1 |
| Omotoye, OO | 1 |
| Oyabambi, AO | 1 |
| Olatunji, LA | 1 |
| Sidhu, HS | 1 |
| Srinivas, R | 1 |
| Sadhotra, A | 1 |
| Belcastro, V | 1 |
| D'Egidio, C | 2 |
| Striano, P | 1 |
| Verrotti, A | 5 |
| Aly, RH | 1 |
| Amr, NH | 1 |
| Saad, WE | 1 |
| Megahed, AA | 1 |
| Sathiya Priya, C | 1 |
| Bhavani, K | 1 |
| Anuradha, CV | 1 |
| Khan, S | 1 |
| Kumar, S | 1 |
| Jena, G | 1 |
| Sedky, AA | 1 |
| El Serafy, OMH | 1 |
| Hassan, OA | 1 |
| Abdel-Kawy, HS | 1 |
| Hasanin, AH | 1 |
| Raafat, MH | 1 |
| Elmslie, JL | 1 |
| Porter, RJ | 1 |
| Joyce, PR | 1 |
| Hunt, PJ | 1 |
| Shand, BI | 1 |
| Scott, RS | 1 |
| la Torre, R | 1 |
| Trotta, D | 2 |
| Mohn, A | 3 |
| Chiarelli, F | 4 |
| Masuccio, F | 1 |
| Chiavaroli, V | 1 |
| de Giorgis, T | 1 |
| Giannini, C | 1 |
| Coppola, G | 1 |
| Mania, M | 1 |
| Javashvili, L | 1 |
| Kasradze, S | 1 |
| Okujava, N | 1 |
| Phabphal, K | 1 |
| Limapichat, K | 1 |
| Sathirapanya, P | 1 |
| Setthawatcharawanich, S | 1 |
| Geater, A | 1 |
| Rauchenzauner, M | 2 |
| Laimer, M | 1 |
| Wiedmann, M | 1 |
| Tschoner, A | 1 |
| Salzmann, K | 1 |
| Sturm, W | 1 |
| Sandhofer, A | 1 |
| Walser, G | 1 |
| Luef, G | 4 |
| Ebenbichler, CF | 2 |
| Abraham, I | 2 |
| Haslinger, M | 1 |
| Trinka, E | 2 |
| Seppi, K | 1 |
| Unterberger, I | 2 |
| Alge, A | 1 |
| Windisch, J | 1 |
| Lechleitner, M | 2 |
| Bauer, G | 2 |
| Hoppichler, F | 2 |
| Pylvänen, V | 2 |
| Knip, M | 2 |
| Pakarinen, AJ | 1 |
| Turkka, J | 2 |
| Kotila, M | 2 |
| Rättyä, J | 1 |
| Myllylä, VV | 1 |
| Isojärvi, JI | 2 |
| Ding, MP | 1 |
| Bao, YY | 1 |
| Chen, Z | 1 |
| Liu, ZR | 1 |
| Xu, LL | 1 |
| Rasgon, NL | 2 |
| Reynolds, MF | 2 |
| Elman, S | 1 |
| Saad, M | 1 |
| Frye, MA | 1 |
| Bauer, M | 1 |
| Altshuler, LL | 1 |
| Tan, H | 1 |
| Orbak, Z | 1 |
| Kantarci, M | 1 |
| Koçak, N | 1 |
| Karaca, L | 1 |
| Kim, JY | 1 |
| Lee, HW | 1 |
| Bahtiyar, G | 1 |
| Weiss, K | 1 |
| Sacerdote, AS | 1 |
| Sisk, EC | 1 |
| Haberlandt, E | 1 |
| Scholl-Bürgi, S | 1 |
| Ernst, B | 1 |
| Karall, D | 1 |
| Rostasy, K | 1 |
| Gungor, S | 1 |
| Yücel, G | 1 |
| Akinci, A | 1 |
| Tabel, Y | 1 |
| Ozerol, IH | 1 |
| Yologlu, S | 1 |
| Piontek, CM | 1 |
| Wisner, KL | 1 |
| Genton, P | 1 |
| Bauer, J | 1 |
| Duncan, S | 1 |
| Taylor, AE | 1 |
| Balen, AH | 1 |
| Eberle, A | 1 |
| Pedersen, B | 1 |
| Salas-Puig, X | 1 |
| Sauer, MV | 1 |
| Pakarinen, A | 1 |
| Basciani, F | 1 |
| De Simone, M | 1 |
| Morgese, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
5 reviews available for valproic acid and Insulin Resistance
| Article | Year |
|---|---|
Metabolic and endocrine effects of valproic acid chronic treatment.
Topics: Anticonvulsants; Epilepsy; Humans; Hyperinsulinism; Insulin Resistance; Leptin; Metabolic Syndrome; | 2013 |
Valproate-induced insulin resistance and obesity in children.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Insulin Resistance; Obesity; Valproic Acid; Weight Gain | 2009 |
Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.
Topics: Androgens; Anticonvulsants; Epilepsy; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; | 2011 |
Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Contraceptives, Oral; Epilepsy; Female; Hormone | 2007 |
On the association between valproate and polycystic ovary syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Comorbidity; Epilepsy; Female; Humans; Hyperinsulinism; Insulin | 2001 |
4 trials available for valproic acid and Insulin Resistance
| Article | Year |
|---|---|
Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study.
Topics: Adiponectin; Adolescent; Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Cholesterol; Choles | 2017 |
Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy.
Topics: Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, LDL; Epilepsy; Fem | 2002 |
Fasting serum insulin and lipid levels in men with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Body Mass Index; Carbamazepine; Epilepsy; Fasting; Humans; Hyper | 2003 |
The role of ghrelin in weight gain and growth in epileptic children using valproate.
Topics: Adolescent; Anticonvulsants; Blood Glucose; Body Height; Body Mass Index; Body Weight; C-Peptide; Ch | 2007 |
22 other studies available for valproic acid and Insulin Resistance
| Article | Year |
|---|---|
Insulin Resistance in children on Sodium Valproate - A hospital based cross-sectional study in Indian children.
Topics: Anticonvulsants; Child; Cross-Sectional Studies; Epilepsy; Humans; Insulin Resistance; Valproic Acid | 2023 |
Prevalence and characteristics of polycystic ovarian syndrome in patients with bipolar disorder.
Topics: Bipolar Disorder; Female; Humans; Insulin Resistance; Polycystic Ovary Syndrome; Prevalence; Valproi | 2023 |
Allopurinol and valproic acid improve cardiac triglyceride and Na
Topics: Adenosine Triphosphatases; Aldosterone; Allopurinol; Animals; Contraceptives, Oral, Combined; Female | 2022 |
Insulin resistance in patients on valproic acid: relation to adiponectin.
Topics: Adiponectin; Adolescent; Anticonvulsants; Blood Glucose; Child; Epilepsy, Generalized; Female; Human | 2015 |
High-calorie diet inflates steatogenic effects of valproic acid in mice.
Topics: Animals; Biomarkers; Blood Glucose; Diet, Western; Dietary Carbohydrates; Dietary Fats; Fatty Liver; | 2016 |
Valproic acid reduces insulin-resistance, fat deposition and FOXO1-mediated gluconeogenesis in type-2 diabetic rat.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gluconeogenesis; Insulin Resist | 2016 |
Trimetazidine potentiates the antiepileptic activity and ameliorates the metabolic changes associated with pentylenetetrazole kindling in rats treated with valproic acid.
Topics: Animals; Anticonvulsants; Aorta; Biomarkers; Blood Glucose; Drug Synergism; Epilepsy; Hippocampus; I | 2017 |
Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
Topics: Adiponectin; Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Comorb | 2009 |
Weight gain and insulin resistance in children treated with valproate: the influence of time.
Topics: Anticonvulsants; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Homeostas | 2010 |
Fasting insulin and HOMA-index changes in patients treated with valproic acid.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Carbamazepine; Cholesterol, HDL; Epilepsy; Female; | 2011 |
Characterization of glucose homeostasis and lipid profile in adult, seizure-free, epileptic patients in Asian population.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Asian People; Blood Glucose; Cholesterol, LDL; Cross-Secti | 2012 |
The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep?
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Diabetes Mellitus, Type 2; Fatty Liver; Female; Glu | 2013 |
Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Insulin Resistance; Obesity; Polycy | 2002 |
[Insulin resistance in epileptic patients during treatment of valproic acid].
Topics: Adult; Body Mass Index; Epilepsy; Female; Humans; Insulin Resistance; Male; Valproic Acid; Weight Ga | 2004 |
Longitudinal evaluation of reproductive function in women treated for bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cross-Sectional Studies | 2005 |
Valproate-induced insulin resistance in prepubertal girls with epilepsy.
Topics: Adolescent; Androstenedione; Anticonvulsants; Blood Glucose; Body Mass Index; Child; Cross-Sectional | 2005 |
Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Carbamazepine; Comorbidity; Epil | 2007 |
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adult; Aged; Antipsychotic Agents; Cortodo | 2007 |
Adiponectin and visfatin concentrations in children treated with valproic acid.
Topics: Adiponectin; Adipose Tissue; Age Factors; Anticonvulsants; Blood Glucose; Child; Epilepsy; Female; H | 2008 |
Appropriate clinical management of women taking valproate.
Topics: Adult; Age Factors; Anticonvulsants; Body Weight; Epilepsy; Female; Humans; Hyperandrogenism; Insuli | 2000 |
Serum insulin and leptin levels in valproate-associated obesity.
Topics: Adult; Body Mass Index; Body Weight; Epilepsy; Female; Humans; Insulin; Insulin Resistance; Leptin; | 2002 |
Insulin resistance in epileptic girls who gain weight after therapy with valproic acid.
Topics: Androgens; Anticonvulsants; Blood Glucose; Body Mass Index; Child; Epilepsy; Female; Follicle Stimul | 2002 |